Accordingly, in these cancers, aberrant NF-κB activation generally stems from genetic abnormalities targeting conventional tumour-suppressor and oncogenic mechanisms, such as RAS and PTEN mutations, and/or the steady exposure of tumour cells to inflammatory stimuli and other cues emanating from the TME (DiDonato et al., 2012). This evidence concerns the gene NFKB1 and cancer.